These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29495904)

  • 21. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is it time to routinely incorporate MRD into practice?
    Ravandi F
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):396-400. PubMed ID: 30466755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
    Pettit K; Stock W; Walter RB
    Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
    Buccisano F; Maurillo L; Gattei V; Del Poeta G; Del Principe MI; Cox MC; Panetta P; Consalvo MI; Mazzone C; Neri B; Ottaviani L; Fraboni D; Tamburini A; Lo-Coco F; Amadori S; Venditti A
    Leukemia; 2006 Oct; 20(10):1783-9. PubMed ID: 16838027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
    Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
    Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
    Norkin M; Katragadda L; Zou F; Xiong S; Chang M; Dai Y; Hsu JW; Moreb JS; Leather H; Murthy HS; Farhadfar N; Li Y; Hromas R; Brown RA; Cogle CR; Wingard JR
    Blood Cancer J; 2017 Nov; 7(12):634. PubMed ID: 29176662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New approaches for the detection of minimal residual disease in acute myeloid leukemia.
    van Rhenen A; Moshaver B; Ossenkoppele GJ; Schuurhuis GJ
    Curr Hematol Malig Rep; 2007 May; 2(2):111-8. PubMed ID: 20425359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression.
    Rossi G; Carella AM; Minervini MM; di Nardo F; Waure Cd; Greco MM; Merla E; Cillis GP; Di Renzo N; Melpignano A; Capalbo S; Palumbo G; Pisapia G; Cascavilla N
    Leuk Res; 2015 Feb; 39(2):138-43. PubMed ID: 25498507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?
    Luskin MR; Stone RM
    J Oncol Pract; 2017 Aug; 13(8):471-480. PubMed ID: 28796964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal residual disease in acute myeloid leukemia: coming of age.
    Paietta E
    Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
    Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
    Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
    Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
    J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
    Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Skou AS; Juul-Dam KL; Ommen HB; Hasle H
    Br J Haematol; 2021 Nov; 195(3):310-327. PubMed ID: 33851435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Significance of Monitoring Minimal Residual Disease by Flow Cytometry in Acute Leukemia Patients Underwent Nonmyeloablative Allo-HSCT].
    Liu XX; Liu TQ; Guo M; Sun QY; Qiao JH; Hu KX; Li BX; Yao B; Yu CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):873-879. PubMed ID: 28641652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating measurable residual disease in acute myeloid leukemia.
    Ravandi F; Walter RB; Freeman SD
    Blood Adv; 2018 Jun; 2(11):1356-1366. PubMed ID: 29895626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.